We are busy packing our baggages for the upcoming PEGS Boston conference April 30 – May 4, at Seaport World Trade Center in Boston, MA.
PEGS: The Essential Protein Engineering Summit is one of the most prestige and preeminent events we go to every year. In this year’s meeting, our co-founder and CEO, Mingjie, will give a 30 minutes talk at 11:50am, Monday, April 30 on how our REmAB™ Antibody Protein Sequencing Service may help in cancer research and therapy. Mingjie will talk about the goal, the challenges and our REmAb™ approach towards antibody protein sequencing, the world’s most advanced antibody protein sequencing platform. He will then explain the technology in greater details and share the experiences and best practices we developed during our journey.
We invite you for a discussion at our booth # 508 and pick up your own “KEEP CALM, GO WILD” t-shirt! (Warning: quantity is very limited!)
You can always setup a meeting with us on how we may help in your research project via this form.
Learn more on:
Antibody Sequencing Services
Antibody Sequencing plus Expression Services
Newsletter for All Things Protein Sequencing
Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics